EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients

Jorge Boán, Carlos Aizpurúa, Isabel Rodríguez-Goncer, Francisco López-Medrano, Rafael San-Juan, Mario Fernández-Ruiz, Eduardo Aparicio-Minguijón, José Manuel Caro-Teller, Carlos Andrés Quezada, Rodrigo Alonso, María Dolores García-Cosío, Amado Andrés und 2 weitere

Enfermedades infecciosas y microbiologia clinica (English ed.) · 2026-05 · 44 (5) · 503145

DOI: 10.1016/j.eimce.2026.503145 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Enfermedades infecciosas y microbiologia clinica (English ed.), 2026-05. Verfasst von Jorge Boán und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Infectious Diseases, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain; Centro…. Hauptthemen laut MEDLINE: Antiviral Agents, Benzimidazoles, Cytomegalovirus Infections, Organ Transplantation. Die Arbeit nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION: Infection due to cytomegalovirus (CMV) frequently complicates the course of solid organ transplantation (SOT). The use of currently available antivirals is often limited due to toxicity. Maribavir (MBV) has demonstrated efficacy in clearing CMV DNAemia, with a favorable safety profile in SOT recipients. Nevertheless, real-life experience outside the clinical trial setting is still scarce. METHODS: A retrospective observational study was conducted including adult SOT recipients who experienced CMV infection and were treated with MBV at our institution between April 2023 and March 2025. RESULTS: Nineteen episodes of CMV infection diagnosed in 16 SOT (mostly lung [57.9%] and heart [26.3%]) recipients were treated with MBV (median duration of 48 days [interquartile range: 18.5-63]), primarily as salvage therapy due to previous toxicity (36.8%) or refractoriness or resistance (31.6%). The initial dose had to be subsequently increased (to 800 or 1200mg BID) in 36.8% of episodes. Transient CMV DNAemia blips were common (21.1%) but not associated to treatment failure. Breakthrough DNAemia while on MBV occurred in 36.8% of episodes. Antiviral resistance testing was performed in four episodes, with one case (25.0%) of documented resistance to MBV and ganciclovir. Clinical response was achieved in 72.2% of episodes, and treatment failure occurred in 26.3%. Treatment-emergent adverse events were rare (10.5%). All-cause mortality was 21.1%, with no CMV-attributable deaths. CONCLUSIONS: In the present real-life experience, MBV appears to be a viable and safe alternative as salvage therapy for CMV infection in SOT recipients, although cases of clinical failure and treatment-emergent resistance were observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsBenzimidazolesCytomegalovirus InfectionsOrgan TransplantationPostoperative ComplicationsRibonucleosidesAdultAgedFemaleHumansMaleMiddle AgedBreakthrough InfectionsDichlororibofuranosylbenzimidazoleRetrospective Studies

Stichwörter der Autor:innen

CitomegalovirusCytomegalovirusExperiencia de vida realMaribavirReal-life experienceSolid organ transplantationTerapiaTherapyTrasplante de órgano sólido

Substanzen

Antiviral AgentsBenzimidazolesDichlororibofuranosylbenzimidazolemaribavirRibonucleosides

Autor:innen und Institutionen

  • Unit of Infectious Diseases, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERI…
  • Unit of Infectious Diseases, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • Department of Pharmacy, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • Department of Pulmonology, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • School of Medicine, Universidad Complutense, Madrid, Spain; Department of Cardiology, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.
  • School of Medicine, Universidad Complutense, Madrid, Spain; Department of Nephrology, "12 de Octubre" University Hospital, Instituto de Investigación Hospital "12 de Octubre" (imas12), Madrid, Spain.

Zitieren

APA

Boán, J., Aizpurúa, C., Rodríguez-Goncer, I., López-Medrano, F., San-Juan, R., Fernández-Ruiz, M., Aparicio-Minguijón, E., Caro-Teller, J. M., Quezada, C. A., Alonso, R., García-Cosío, M. D., Andrés, A., de Pablos, A., & Aguado, J. M. (2026). Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients. Enfermedades infecciosas y microbiologia clinica (English ed.), 44(5), 503145. https://doi.org/10.1016/j.eimce.2026.503145

Vancouver

Boán J, Aizpurúa C, Rodríguez-Goncer I, López-Medrano F, San-Juan R, Fernández-Ruiz M, et al. Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients. Enfermedades infecciosas y microbiologia clinica (English ed.). 2026;44(5):503145. doi:10.1016/j.eimce.2026.503145

BibTeX
@article{Bon2026,
  author = {Boán, Jorge and Aizpurúa, Carlos and Rodríguez-Goncer, Isabel and López-Medrano, Francisco and San-Juan, Rafael and Fernández-Ruiz, Mario and Aparicio-Minguijón, Eduardo and Caro-Teller, José Manuel and Quezada, Carlos Andrés and Alonso, Rodrigo and García-Cosío, María Dolores and Andrés, Amado and de Pablos, Alicia and Aguado, José María},
  title = {Real-life experience with maribavir for the treatment of cytomegalovirus infection in solid organ transplant recipients},
  journal = {Enfermedades infecciosas y microbiologia clinica (English ed.)},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {503145},
  doi = {10.1016/j.eimce.2026.503145}
}
Kostenlos starten →